There is also evidence that upregulation of Src expression and/or signalling is associated with resistance to many classes of anti-cancer drugs (Mayer and Krop, 2010) including those targeted against HER-2 (Peiro et al, 2014) and EGFR (Wheeler et al, 2009b), and that combination of Src inhibitors with such agents may reverse or prevent the occurrence of such resistance (Zhang et al, 2011). Here, SRC is linked to cancer.